CD274 and neoplasm: Atezolizumab monotherapy significantly prolongs overall survival compared to platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression (≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells) [4].